Kite Pharma enrols first patient in ZUMA-6

Kite Pharma has enrolled the first patient of ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with Genentech ’s anti-PD-L1 cancer immunotherapy atezolizumab.

Source: Drug Development Technology - October 9, 2016 Category: Pharmaceuticals Source Type: news